Reporter brief
RCT of mTORC1 inhibitor everolimus safety and effects on aging markers in older adults
What happened
This randomized controlled trial tested whether 24 weeks of mTORC1 inhibition via everolimus (0.5 mg daily or 5 mg weekly) could improve physiological and molecular hallmarks of aging. Participants aged 55-80 with insulin resistance or prediabetes received active treatment; a younger comparison group (ages 18-35) did not receive intervention.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Participants aged 55-80 years old who are insulin resistant or prediabetic (intervention group); Participants aged 18-35 (non-intervention control group)
- Design
- Rct
- Sample
- —
- Journal
- University of Wisconsin, Madison
- Published
- Sep 4, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.